IL312539A - Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 - Google Patents

Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2

Info

Publication number
IL312539A
IL312539A IL312539A IL31253924A IL312539A IL 312539 A IL312539 A IL 312539A IL 312539 A IL312539 A IL 312539A IL 31253924 A IL31253924 A IL 31253924A IL 312539 A IL312539 A IL 312539A
Authority
IL
Israel
Prior art keywords
cov
sars
vaccines
medical
diseases caused
Prior art date
Application number
IL312539A
Other languages
English (en)
Hebrew (he)
Inventor
Peter Ebert
Agnete Fredriksen
Mark Klinger
Gunnstein Norheim
Edward Osborne
Monika Sekelja
Thomas Snyder
Elisabeth Stubsrud
Original Assignee
Adaptive Biotechnologies Corp
Nykode Therapeutics ASA
Peter Ebert
Agnete Fredriksen
Mark Klinger
Gunnstein Norheim
Edward Osborne
Monika Sekelja
Thomas Snyder
Elisabeth Stubsrud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptive Biotechnologies Corp, Nykode Therapeutics ASA, Peter Ebert, Agnete Fredriksen, Mark Klinger, Gunnstein Norheim, Edward Osborne, Monika Sekelja, Thomas Snyder, Elisabeth Stubsrud filed Critical Adaptive Biotechnologies Corp
Publication of IL312539A publication Critical patent/IL312539A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL312539A 2021-11-03 2022-11-03 Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2 IL312539A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163275015P 2021-11-03 2021-11-03
US202263377087P 2022-09-26 2022-09-26
PCT/EP2022/080679 WO2023079001A1 (en) 2021-11-03 2022-11-03 Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2

Publications (1)

Publication Number Publication Date
IL312539A true IL312539A (en) 2024-07-01

Family

ID=84365420

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312539A IL312539A (en) 2021-11-03 2022-11-03 Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2

Country Status (9)

Country Link
US (1) US20250049910A1 (cg-RX-API-DMAC10.html)
EP (1) EP4426344A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024540322A (cg-RX-API-DMAC10.html)
KR (1) KR20240110821A (cg-RX-API-DMAC10.html)
AU (1) AU2022381515A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235174A1 (cg-RX-API-DMAC10.html)
IL (1) IL312539A (cg-RX-API-DMAC10.html)
MX (1) MX2024005408A (cg-RX-API-DMAC10.html)
WO (1) WO2023079001A1 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215489B2 (en) 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
WO2011161244A1 (en) 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
EP3533462A1 (en) 2011-12-21 2019-09-04 Vaccibody AS Vaccines against hpv
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
CN113631185A (zh) 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
PH12022552164A1 (en) * 2020-02-19 2023-11-29 United Biomedical Inc Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)
US20230218741A1 (en) * 2020-03-31 2023-07-13 The Children's Hospital Of Philadelphia Sars-cov-2 vaccines for population-scale immunity

Also Published As

Publication number Publication date
JP2024540322A (ja) 2024-10-31
WO2023079001A1 (en) 2023-05-11
AU2022381515A1 (en) 2024-05-09
CA3235174A1 (en) 2023-05-11
US20250049910A1 (en) 2025-02-13
KR20240110821A (ko) 2024-07-16
EP4426344A1 (en) 2024-09-11
MX2024005408A (es) 2024-08-06

Similar Documents

Publication Publication Date Title
EP4366768A4 (en) Pan-human coronavirus vaccines
MX2018014573A (es) Vacuna contra el virus del zika.
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
IL262702B (en) Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
MX2013004817A (es) Enfermedad inflamatoria.
CY1116511T1 (el) Μεθοδος αγωγης του κολπικου ινιδισμου
MX395637B (es) Composiciones de alergenos alimentarios.
IL282227A (en) Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery
ZA201801300B (en) Composition and medical device comprising acetylsalicylic acid for the treatment of human papilloma virus skin infections
MX2017002825A (es) Tratamientos medicos a base de anamorelina.
EP4423288A4 (en) COMPOSITIONS AND METHODS OF THERAPEUTIC OR VACCINAL ADMINISTRATION
EP4251278A4 (en) HUMAN PAPILLOMAVIRUS VACCINES AND THEIR USES FOR HPV-ASSOCIATED DISEASES
IL280550A (en) A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
MX2011007386A (es) Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica.
HK40116587A (en) Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2
EP4499105A4 (en) IMPROVED FORMULATION OF THIOPURINE AND TREATMENT METHODS
DK4106783T3 (da) Sammensætning til behandling af hud- og slimhindesygdomme
CU20100083A7 (es) Tolerogenos adyuvados como vacuna de malaria
PH12017500928A1 (en) A rabies composition comprising pika adjuvant
MX2025013368A (es) Vacuna contra el virus respiratorio sincitial y métodos de uso
IL311672A (en) Dioxazines and their use in treatment of gba-related diseases
EP4055176A4 (en) Anti-gucy2c vaccines and vaccination
IL311671A (en) Pyridines and their use in treatment of gba-related diseases
KR102204642B9 (ko) 인공 호흡시 의료진 감염을 방지하기 위한 장치
IL311669A (en) Oximes and their use in treatment of gba-related diseases